
Gilead Sciences (GILD) Stock Forecast & Price Target
Gilead Sciences (GILD) Analyst Ratings
Bulls say
Gilead Sciences is positioned for a positive financial outlook due to several key developments, including the anticipated launch of Trodelvy for first-line metastatic triple-negative breast cancer in the second half of 2026, which is expected to significantly enhance its oncology pipeline and revenue streams. The company has already exceeded its 90% payer coverage goal six months ahead of schedule and is experiencing strong revenue growth within its HIV franchise, projecting a consistent 6% year-over-year increase moving into 2026. Additionally, the encouraging sales growth of Livdelzi and the robust expansion of the HIV PrEP market, alongside disciplined operating expenses and improving operating margins, suggest the potential for sustained financial strength and resilience for Gilead Sciences.
Bears say
Gilead Sciences has revised its revenue guidance for Veklury, reducing its forecast for FY25 to $1 billion from $1.4 billion, and predicts a further decline to $600 million by 2026, indicating a significant and ongoing downward trend in sales. The cell therapy segment is also under pressure, with a reported revenue decline of 6% year-over-year, and Gilead expects a 10% year-over-year decrease in this category for 2026 due to increasing competition and policy-related challenges. Additionally, the overall sales trajectory from Veklury has become less impactful on total revenues, reflecting a shift in Gilead's business landscape as competitive pressures mount and revenue declines continue to affect performance.
This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.
Gilead Sciences (GILD) Analyst Forecast & Price Prediction
Start investing in Gilead Sciences (GILD)
Order type
Buy in
Order amount
Est. shares
0 shares